
A


0.8
0.6
0.4
0.2
0.0
OD 405
2
3
4
5
6
Log(X)
-48h
-24h
+24h
+48h
+72h
Before SADC application
After SADC application





LogIC50
4
3,5
3
2,5
2
1,5
-48h
-24h
+24h
+48h
+72h
SADC application

Fig. 1


B



0.8
0.6
0.4
0.2
0.0
OD 405
2
3
4
5
6
Log(X)
-48h
-24h
Before SADC application
+24h
+48h
+72h
After SADC application


LogIC50
3
2,8
2,6
2,4
2,2
-48h
-24h
+24h
+48h
+72h
SADC application

Cont. Fig. 1


C



0.8
0.6
0.4
0.2
0.0
OD 405
2
3
4
5
6
Log(X)
-48h
-24h
Before SADC application
+24h
+48h
+72h
After SADC application


LogIC50
3
2,5
2
1,5
1
0,5
0
-48h
-24h
+24h
+48h
+72h
SADC application

Cont. Fig. 1


D



0.8
0.6
0.4
0.2
0.0
OD 405
2
3
4
5
6
Log(X)
-48h
-24h
+24h
+48h
+72h
Before SADC application
After SADC application


LogIC50
3,5
3
2,5
2
1,5
1
0,5
0
-48h
-24h
+24h
+48h
+72h
SADC application

Cont. Fig. 1

E


0.8
0.6
0.4
0.2
0.0
OD 405
2
3
4
5
6
Log(X)
-48h
-24h
Before SADC application
+24h
+48h
+72h
+96h
After SADC application


LogIC50
4,5
4
3,5
3
2,5
2
1,5
1
0,5
0
-48h
-24h
+24h
+48h
+72h
SADC applicatiton

Cont. Fig. 1




Fig. 2



2.0
1.5
1.0
0.5
0.0
OD 450 nm
****
****
*
before
monovalent
divalent
neg. control

Fig. 3



SADC_CTR
SADC-ALB
SADC-IG
SADC-HP
SADC-TF
fold reductoin
1,2
1,0
0,8
0,6
0,4
0,2
0,0
0
24
48
72
96
120
hours after SADC injection

Fig. 4



6000
4000
2000
0
ng/ml SADC
SADC-ALB
SADC-IG
SADC-HP
SADC-TF
SADC-CTR

Fig. 5



1.5
1.0
0.5
0.0
OD 450 nm
SADC-ALB
SADC-HP
SADC-TF
SADC-CTR

Fig. 6



2.5
2.0
1.5
1.0
0.5
0.0
OD 450 nm
0
500
1000
1500
2000
2500
ng/ml SADC
SADC-ALB
SADC-IG
SADC-HP
SADC-TF
SADC-CTR

Fig. 7



A
OD 450 nm
log ng/ml SADC
SADC-ALB
SADC-HP
SADC-TF
SADC-CTR
B
EC50 (ng/ml SADC)
SADC-ALB
SADC-HP
SADC-TF

Fig. 8



125
100
75
50
25
0
% antibody
0 12 24 36 48 60 72 84 96 108 120
hours
Mac2-158
E10B10

Fig. 9



kDa
1 2 3 4 5 6
250
150
100
75

Fig. 10



750 Da PEG-SADC
2 kDa PEG-SADC
5 kDa PEG-SADC
10 kDa PEG-SADC
PEG 10 kDa
hu-apo-TF
T24
T36
T48
T72
T96
T120
130
100
50
0
%antibody

Fig. 11



2 kDa PEG-SADC
5 kDa PEG-SADC
10 kDa PEG-SADC
positive control
OD 450 nm
2.0
1.5
1.0
0.5
0.0
0
7
14
21
28
days

Fig. 12



% free antibody
control
10 kDa PEG-SADC
2 kDa PEG-SADC
% antibody
120
100
80
60
40
20
0
2
4
8
12
24
48
72
96
120
144
168
hours after antibody injection

Fig. 13